Valneva to Partner with Instituto Butantan on Single-Shot Chikungunya Vaccine for Low- and Middle- Income Countries

Valneva SE, a specialty vaccine company, and Instituto Butantan, producer of immunobiologic products is preparing to start Phase 3 clinical studies of a single-shot chikungunya vaccine, VLA1553, in the United States later this year.

Experimental HIV Vaccine Regimen Ineffective in Preventing HIV

The Phase 2b/3 study, named HVTN 702 or Uhambo, began in 2016 and was taking place in South Africa.  The study was canceled because independent data and safety monitoring board (DSMB) found during an interim review that the regimen did not prevent HIV.  The board did not express any concern regarding participant safety.